STOCK TITAN

[8-K] Immucell Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.

The new loan is secured by a security interest in substantially all of the Company’s assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.

ImmuCell Corporation ha stipulato un contratto di prestito e una cambiale con Maine Community Bank per un importo totale di $2,327,119 a tasso fisso del 6,5% annuo. I proventi sono stati utilizzati per estinguere un prestito esistente con Maine Community Bank con saldo residuo di $1,525,852 al tasso del 7% e un prestito della Finance Authority of Maine con saldo residuo di $768,209 al tasso del 8%, consolidando così tali obbligazioni in un unico finanziamento.

Il nuovo prestito è garantito da un diritto di garanzia sulla quasi totalità delle attività della Società, e il creditore può richiedere l'immediato rimborso se la Società non effettua pagamenti nei termini o non rispetta le condizioni del prestito. Il contratto di prestito e la cambiale sono depositati come Allegati 10.1 e 10.2, e un comunicato stampa correlato è depositato come Allegato 99.1.

ImmuCell Corporation celebró un Contrato de Préstamo y un Pagaré con Maine Community Bank por un monto total de $2,327,119 a una tasa fija de interés del 6.5% anual. Los fondos se utilizaron para liquidar un préstamo existente con Maine Community Bank con un saldo pendiente de $1,525,852 con interés del 7% y un préstamo de la Finance Authority of Maine con un saldo pendiente de $768,209 con interés del 8%, consolidando efectivamente esas obligaciones en un solo préstamo.

El nuevo préstamo está garantizado mediante un gravamen sobre prácticamente todos los activos de la Compañía, y el prestamista puede acelerar el reembolso si la Compañía no realiza los pagos a tiempo o no cumple con los términos del préstamo. El Contrato de Préstamo y el Pagaré se presentan como Anexos 10.1 y 10.2, y un comunicado de prensa relacionado se presenta como Anexo 99.1.

ImmuCell Corporation은 Maine Community Bank와 총 대출금액 $2,327,119, 고정 연이율 6.5%의 대출계약서와 약속어음을 체결했습니다. 대출금은 이율 7%로 잔액 $1,525,852가 남아 있던 기존 Maine Community Bank 대출과 이율 8%로 잔액 $768,209가 남아 있던 Finance Authority of Maine 대출을 상환하는 데 사용되어, 해당 채무들을 하나의 대출로 통합했습니다.

새 대출은 회사의 사실상 모든 자산에 대한 담보권으로 담보되며, 회사가 기한 내에 상환하지 않거나 대출 조건을 준수하지 않을 경우 대출자는 상환을 가속화할 수 있습니다. 대출계약서와 약속어음은 각각 증빙서류 10.110.2로 제출되었고, 관련 보도자료는 증빙서류 99.1로 제출되었습니다.

ImmuCell Corporation a conclu un contrat de prêt et un billet à ordre avec Maine Community Bank pour un montant total de $2,327,119 à un taux d'intérêt fixe de 6,5% par an. Les fonds ont été utilisés pour rembourser un prêt existant auprès de Maine Community Bank présentant un solde impayé de $1,525,852 et un taux d'intérêt de 7%, ainsi qu'un prêt de la Finance Authority of Maine avec un solde impayé de $768,209 et un taux d'intérêt de 8%, consolidant ainsi ces engagements en un seul prêt.

Le nouveau prêt est garanti par un droit réel sur pratiquement l'ensemble des actifs de la Société, et le prêteur peut exiger le remboursement anticipé si la Société manque de verser les paiements à temps ou ne respecte pas les conditions du prêt. Le contrat de prêt et le billet à ordre sont déposés en tant qu'annexes 10.1 et 10.2, et un communiqué de presse associé est déposé en tant qu'annexe 99.1.

Die ImmuCell Corporation hat mit der Maine Community Bank einen Darlehensvertrag und eine Schuldscheinvereinbarung über eine Gesamtdarlehenssumme von $2,327,119 zu einem festen Zinssatz von 6,5% p.a. abgeschlossen. Die Mittel wurden verwendet, um ein bestehendes Darlehen bei der Maine Community Bank mit einem ausstehenden Saldo von $1,525,852 und einem Zinssatz von 7% sowie ein Darlehen der Finance Authority of Maine mit einem ausstehenden Saldo von $768,209 und einem Zinssatz von 8% abzulösen, wodurch diese Verbindlichkeiten effektiv in ein einziges Darlehen konsolidiert wurden.

Das neue Darlehen ist durch eine Sicherung auf im Wesentlichen alle Vermögenswerte des Unternehmens besichert, und der Kreditgeber kann die Rückzahlung beschleunigen, falls das Unternehmen Zahlungen nicht fristgerecht leistet oder anderweitig gegen die Kreditbedingungen verstößt. Der Darlehensvertrag und der Schuldschein sind als Anlagen 10.1 und 10.2 eingereicht, und eine zugehörige Pressemitteilung ist als Anlage 99.1 eingereicht.

Positive
  • $2,327,119 loan at a fixed 6.5% interest rate consolidates prior higher-rate debt
  • Proceeds were used to repay an MCB loan of $1,525,852 at 7% and a FAME loan of $768,209 at 8%, simplifying obligations
  • Definitive agreements (Loan Agreement and Promissory Note) are filed as Exhibits 10.1 and 10.2
Negative
  • The loan is secured by a security interest in substantially all of the Company’s assets, increasing secured creditor claims
  • Maine Community Bank may accelerate repayment on failure to make timely payments or comply with agreement terms
  • Filing does not disclose maturity, amortization schedule, or covenants, limiting assessment of liquidity and covenant risk

Insights

TL;DR: Consolidation into a $2.33M loan at 6.5% reduces headline interest rates versus prior debt but creates a single secured obligation.

The Company replaced two higher-rate loans (7% and 8%) with a single fixed-rate borrowing of $2,327,119 at 6.5%. This should reduce ongoing interest expense on the refinanced balances compared to the prior rates stated in the filing. The transaction centralizes repayment obligations with Maine Community Bank and is evidenced by a Loan Agreement and Promissory Note filed as Exhibits 10.1 and 10.2. The analysis is limited to the terms disclosed in the filing; no additional financial statement impact or covenant detail is provided in the text.

TL;DR: The new loan is secured by substantially all assets, increasing secured exposure and giving the lender acceleration rights on default.

The filing explicitly states the loan is secured by a security interest in substantially all Company assets and that failure to make timely payments or to comply with agreement terms permits acceleration and demand for full repayment. Those provisions raise creditor-enforcement risk if liquidity pressures arise. The filing does not disclose covenants, collateral specifics, amortization schedule, or maturity, so a full risk assessment cannot be completed from the provided text alone.

ImmuCell Corporation ha stipulato un contratto di prestito e una cambiale con Maine Community Bank per un importo totale di $2,327,119 a tasso fisso del 6,5% annuo. I proventi sono stati utilizzati per estinguere un prestito esistente con Maine Community Bank con saldo residuo di $1,525,852 al tasso del 7% e un prestito della Finance Authority of Maine con saldo residuo di $768,209 al tasso del 8%, consolidando così tali obbligazioni in un unico finanziamento.

Il nuovo prestito è garantito da un diritto di garanzia sulla quasi totalità delle attività della Società, e il creditore può richiedere l'immediato rimborso se la Società non effettua pagamenti nei termini o non rispetta le condizioni del prestito. Il contratto di prestito e la cambiale sono depositati come Allegati 10.1 e 10.2, e un comunicato stampa correlato è depositato come Allegato 99.1.

ImmuCell Corporation celebró un Contrato de Préstamo y un Pagaré con Maine Community Bank por un monto total de $2,327,119 a una tasa fija de interés del 6.5% anual. Los fondos se utilizaron para liquidar un préstamo existente con Maine Community Bank con un saldo pendiente de $1,525,852 con interés del 7% y un préstamo de la Finance Authority of Maine con un saldo pendiente de $768,209 con interés del 8%, consolidando efectivamente esas obligaciones en un solo préstamo.

El nuevo préstamo está garantizado mediante un gravamen sobre prácticamente todos los activos de la Compañía, y el prestamista puede acelerar el reembolso si la Compañía no realiza los pagos a tiempo o no cumple con los términos del préstamo. El Contrato de Préstamo y el Pagaré se presentan como Anexos 10.1 y 10.2, y un comunicado de prensa relacionado se presenta como Anexo 99.1.

ImmuCell Corporation은 Maine Community Bank와 총 대출금액 $2,327,119, 고정 연이율 6.5%의 대출계약서와 약속어음을 체결했습니다. 대출금은 이율 7%로 잔액 $1,525,852가 남아 있던 기존 Maine Community Bank 대출과 이율 8%로 잔액 $768,209가 남아 있던 Finance Authority of Maine 대출을 상환하는 데 사용되어, 해당 채무들을 하나의 대출로 통합했습니다.

새 대출은 회사의 사실상 모든 자산에 대한 담보권으로 담보되며, 회사가 기한 내에 상환하지 않거나 대출 조건을 준수하지 않을 경우 대출자는 상환을 가속화할 수 있습니다. 대출계약서와 약속어음은 각각 증빙서류 10.110.2로 제출되었고, 관련 보도자료는 증빙서류 99.1로 제출되었습니다.

ImmuCell Corporation a conclu un contrat de prêt et un billet à ordre avec Maine Community Bank pour un montant total de $2,327,119 à un taux d'intérêt fixe de 6,5% par an. Les fonds ont été utilisés pour rembourser un prêt existant auprès de Maine Community Bank présentant un solde impayé de $1,525,852 et un taux d'intérêt de 7%, ainsi qu'un prêt de la Finance Authority of Maine avec un solde impayé de $768,209 et un taux d'intérêt de 8%, consolidant ainsi ces engagements en un seul prêt.

Le nouveau prêt est garanti par un droit réel sur pratiquement l'ensemble des actifs de la Société, et le prêteur peut exiger le remboursement anticipé si la Société manque de verser les paiements à temps ou ne respecte pas les conditions du prêt. Le contrat de prêt et le billet à ordre sont déposés en tant qu'annexes 10.1 et 10.2, et un communiqué de presse associé est déposé en tant qu'annexe 99.1.

Die ImmuCell Corporation hat mit der Maine Community Bank einen Darlehensvertrag und eine Schuldscheinvereinbarung über eine Gesamtdarlehenssumme von $2,327,119 zu einem festen Zinssatz von 6,5% p.a. abgeschlossen. Die Mittel wurden verwendet, um ein bestehendes Darlehen bei der Maine Community Bank mit einem ausstehenden Saldo von $1,525,852 und einem Zinssatz von 7% sowie ein Darlehen der Finance Authority of Maine mit einem ausstehenden Saldo von $768,209 und einem Zinssatz von 8% abzulösen, wodurch diese Verbindlichkeiten effektiv in ein einziges Darlehen konsolidiert wurden.

Das neue Darlehen ist durch eine Sicherung auf im Wesentlichen alle Vermögenswerte des Unternehmens besichert, und der Kreditgeber kann die Rückzahlung beschleunigen, falls das Unternehmen Zahlungen nicht fristgerecht leistet oder anderweitig gegen die Kreditbedingungen verstößt. Der Darlehensvertrag und der Schuldschein sind als Anlagen 10.1 und 10.2 eingereicht, und eine zugehörige Pressemitteilung ist als Anlage 99.1 eingereicht.

false 0000811641 0000811641 2025-08-07 2025-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) August 07, 2025

 

ImmuCell Corporation
(Exact name of registrant as specified in its charter)

 

DE   001-12934   01-0382980
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

56 Evergreen Drive Portland, Maine   04103
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code 207-878-2770

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.10 par value per share   ICCC   The NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

On August 7, 2025, ImmuCell Corporation (the “Company”) entered into a Loan Agreement, Promissory Note, and other definitive agreements covering a loan transaction with Maine Community Bank (MCB). Proceeds from such loan transaction in the principal amount of $2,327,119, and bearing interest at a fixed rate of 6.5% per annum, were used to pay off a loan from MCB with an outstanding balance of $1,525,852 that was bearing interest at a fixed rate of 7% per annum and a loan from the Finance Authority of Maine (FAME) with an outstanding balance of $768,209 that was bearing interest at a fixed rate of 8% per annum.

 

The loan is secured by a security interest with respect to substantially all of the Company’s assets. The Company’s failure to make timely payments of principal and interest, or otherwise comply with the terms of its agreements with MCB, would entitle MCB to accelerate the maturity of such debt and demand repayment in full.

 

The foregoing descriptions of the Loan Agreement and the Promissory Note are qualified in their entirety by reference to the Loan Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference, and to the Promissory Note, which is filed as Exhibit 10.2 hereto and incorporated herein by reference.

 

Item 9.01. Exhibits.

 

(d) Exhibits.

 

10.1 Loan Agreement between the Company and Maine Community Bank dated as of August 7, 2025.
10.2 Promissory Note executed by the Company in favor of Maine Community Bank dated as of August 7, 2025.
99.1 Press Release of the Company dated August 12, 2025.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUCELL CORPORATION
   
Date: August 12, 2025 By: /s/ Michael F. Brigham
    Michael F. Brigham
    President and Chief Executive Officer
     
Date: August 12, 2025 By: /s/ Timothy C. Fiori
    Timothy C. Fiori
    Chief Financial Officer

 

2

 

 

Exhibit Index

 

Exhibit No.

  Description
10.1   Loan Agreement between the Company and Maine Community Bank dated as of August 7, 2025.
10.2   Promissory Note executed by the Company in favor of Maine Community Bank dated as of August 7, 2025.
99.1   Press Release of the Company dated August 12, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

3

 

FAQ

What did ImmuCell (ICCC) disclose in the 8-K?

ImmuCell entered a loan agreement with Maine Community Bank for $2,327,119 at a fixed 6.5% interest rate to repay prior loans of $1,525,852 (MCB at 7%) and $768,209 (FAME at 8%).

How much is the new loan and what is the interest rate?

The new loan principal is $2,327,119 with a fixed interest rate of 6.5% per annum.

Which prior loans were repaid with the proceeds?

Proceeds were used to pay off a Maine Community Bank loan with an outstanding balance of $1,525,852 at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 at 8%.

Is the new loan secured?

Yes. The filing states the loan is secured by a security interest in substantially all of the Company’s assets.

What exhibits were filed with the 8-K?

Exhibits filed include the Loan Agreement (Exhibit 10.1), the Promissory Note (Exhibit 10.2), and a related press release (Exhibit 99.1), plus the cover page interactive data file (104).
Immucell

NASDAQ:ICCC

ICCC Rankings

ICCC Latest News

ICCC Latest SEC Filings

ICCC Stock Data

60.19M
6.51M
27.91%
18.98%
0.21%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
PORTLAND